1. Home
  2. OVID
  3. OVID News

Latest Ovid Therapeutics Inc. (OVID) News on November 17, 2025

OVID

MT Newswires

3 hours ago

Leerink Partners Initiates Ovid Therapeutics at Outperform With $5 Price Target

Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates
OVID

Zacks

5 days ago

Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates

OVID

MT Newswires

5 days ago

Ovid Therapeutics Names Meg Alexander CEO

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
OVID

GlobeNewswire

5 days ago

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Metagenomi, Ovid CEOs step aside; Cogent soars on ‘unprecedented’ stomach cancer data
OVID

BioPharma Dive

5 days ago

Metagenomi, Ovid CEOs step aside; Cogent soars on ‘unprecedented’ stomach cancer data

QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer
OVID

Business Wire

7 days ago

QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer

MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates
OVID

Zacks

12 days ago

MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates

AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates
OVID

Zacks

13 days ago

AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
OVID

Zacks

13 days ago

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

B. Riley Lifts Ovid Therapeutics (OVID) PT to $5 on Strong OV329 Phase 1 Data
OVID

Insider Monkey

22 days ago

B. Riley Lifts Ovid Therapeutics (OVID) PT to $5 on Strong OV329 Phase 1 Data

OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
OVID

Zacks

a month ago

OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data

OVID

MT Newswires

a month ago

Ovid Therapeutics' OV329 Shows Promise as Epilepsy Treatment, Oppenheimer Says

Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know
OVID

Zacks

a month ago

Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know

OVID

MT Newswires

a month ago

Wedbush Adjusts Price Target on Ovid Therapeutics to $5 From $3, Maintains Outperform Rating

Ovid Therapeutics (OVID): Assessing Valuation Following Encouraging OV329 Phase 1 Trial Results
OVID

Simply Wall St.

a month ago

Ovid Therapeutics (OVID): Assessing Valuation Following Encouraging OV329 Phase 1 Trial Results

OVID

MT Newswires

a month ago

Sector Update: Health Care Stocks Gain Friday Afternoon

OVID

MT Newswires

a month ago

Exchange-Traded Funds, Equity Futures Higher Pre-Bell as Investors Eye Another Interest Rate Cut for 2025

OVID

MT Newswires

a month ago

Sector Update: Health Care Stocks Advance Premarket Friday

OVID

MT Newswires

a month ago

Investors Cautious as Government Shutdown Persists, Driving Muted Premarket Action for US Equity Futures

OVID

MT Newswires

a month ago

Ovid Therapeutics Reports 'Positive' Topline Data on OV329 for Drug Resistant Epilepsies

OVID

MT Newswires

a month ago

Ovid Therapeutics Agrees to Financing Deal Worth up to $175 million

OVID

MT Newswires

a month ago

Top Premarket Gainers

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
OVID

GlobeNewswire

5 months ago

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?
OVID

Barchart

5 months ago

Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
OVID

GlobeNewswire

5 months ago

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
OVID

Zacks

6 months ago

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
OVID

GlobeNewswire

6 months ago

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
OVID

Zacks

6 months ago

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
OVID

GlobeNewswire

7 months ago

Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Ovid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
OVID

Simply Wall St.

8 months ago

Ovid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

OVID

MT Newswires

8 months ago

Wedbush Adjusts Price Target on Ovid Therapeutics to $3 From $4, Keeps Outperform Rating

Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates
OVID

Zacks

8 months ago

Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
OVID

GlobeNewswire

8 months ago

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

We're A Little Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate
OVID

Simply Wall St.

8 months ago

We're A Little Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
OVID

GlobeNewswire

9 months ago

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
OVID

GlobeNewswire

9 months ago

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
OVID

GlobeNewswire

9 months ago

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ovid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’
OVID

TipRanks

10 months ago

Ovid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’

OVID

Argus Research

10 months ago

Daily – Vickers Top Buyers & Sellers for 01/30/2025

US Penny Stocks To Watch In January 2025
OVID

Simply Wall St.

10 months ago

US Penny Stocks To Watch In January 2025

OVID

MT Newswires

10 months ago

Oppenheimer Upgrades Ovid Therapeutics to Outperform From Perform, $4 Price Target

Ovid Therapeutics Insider Ups Holding During Year
OVID

Simply Wall St.

10 months ago

Ovid Therapeutics Insider Ups Holding During Year

3 US Penny Stocks With Market Caps Over $20M
OVID

Simply Wall St.

a year ago

3 US Penny Stocks With Market Caps Over $20M

Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting
OVID

GlobeNewswire

a year ago

Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
OVID

Zacks

a year ago

Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
OVID

GlobeNewswire

a year ago

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

US Penny Stocks To Watch This November 2024
OVID

Simply Wall St.

a year ago

US Penny Stocks To Watch This November 2024

Ovid Therapeutics to Host Investor Event
OVID

GlobeNewswire

a year ago

Ovid Therapeutics to Host Investor Event

Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely?
OVID

Simply Wall St.

a year ago

Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely?

Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
OVID

GlobeNewswire

a year ago

Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
OVID

GlobeNewswire

a year ago

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Ovid Therapeutics to Present at Upcoming September Investor Conferences
OVID

GlobeNewswire

a year ago

Ovid Therapeutics to Present at Upcoming September Investor Conferences

Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
OVID

Zacks

a year ago

Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why

Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates
OVID

Zacks

a year ago

Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
OVID

GlobeNewswire

a year ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Lilly opens R&D hub; Ovid and Lexicon lay off staff
OVID

BioPharma Dive

a year ago

Lilly opens R&D hub; Ovid and Lexicon lay off staff

Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
OVID

Zacks

a year ago

Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates

Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
OVID

GlobeNewswire

a year ago

Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer

Ovid Therapeutics to Present at Upcoming August Investor Conferences
OVID

GlobeNewswire

a year ago

Ovid Therapeutics to Present at Upcoming August Investor Conferences

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
OVID

GlobeNewswire

a year ago

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Ovid Therapeutics Inc. (OVID): One of the Best Penny Stocks to Buy Under $1 According to Hedge Funds?
OVID

Insider Monkey

a year ago

Ovid Therapeutics Inc. (OVID): One of the Best Penny Stocks to Buy Under $1 According to Hedge Funds?

eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
OVID

GlobeNewswire

a year ago

eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures

OVID

MT Newswires

a year ago

Immunic Names Jason Tardio as COO, Werner Gladdines as Chief Development Officer

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
OVID

GlobeNewswire

a year ago

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
OVID

Zacks

a year ago

Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News

OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
OVID

Zacks

a year ago

OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies

Apple downgraded, Kroger upgraded: Wall Street's top analyst calls
OVID

The Fly

a year ago

Apple downgraded, Kroger upgraded: Wall Street's top analyst calls

OVID

MT Newswires

a year ago

Oppenheimer Downgrades Ovid Therapeutics to Market Perform

OVID

MT Newswires

a year ago

B. Riley Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating

OVID

MT Newswires

a year ago

BTIG Adjusts Price Target on Ovid Therapeutics to $5 From $11, Maintains Buy Rating

OVID

MT Newswires

a year ago

HC Wainwright Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating

OVID

MT Newswires

a year ago

Citigroup Adjusts Price Target on Ovid Therapeutics to $1.20 From $3.50, Maintains Neutral Rating

OVID

MT Newswires

a year ago

Top Midday Decliners

OVID

MT Newswires

a year ago

Sector Update: Health Care Stocks Decline Premarket Monday

OVID

MT Newswires

a year ago

Wedbush Lowers PT on Ovid Therapeutics to $4 From $8 After Soticlestat Missed Endpoints in Phase 3 Studies; Maintains Outperform Rating

OVID

MT Newswires

a year ago

Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall

Takeda drug for rare types of epilepsy misses goal in late-stage trial
OVID

BioPharma Dive

a year ago

Takeda drug for rare types of epilepsy misses goal in late-stage trial

OVID

MT Newswires

a year ago

Top Premarket Decliners

Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
OVID

GlobeNewswire

a year ago

Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat

[Latest] Global Virtual Reality In Gaming Market Size/Share Worth USD 103,244.7 Million by 2033 at a 16.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
OVID

GlobeNewswire

a year ago

[Latest] Global Virtual Reality In Gaming Market Size/Share Worth USD 103,244.7 Million by 2033 at a 16.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

OVID

Business Wire

a year ago

Net Asset Value(s)

CCF Group Successful €225m AT1 Issuance
OVID

Business Wire

a year ago

CCF Group Successful €225m AT1 Issuance

Should You Hold 908 Devices (MASS)?
OVID

Insider Monkey

a year ago

Should You Hold 908 Devices (MASS)?

Bangladesh Ecommerce Market Report 2024, Featuring Daraz Bangladesh, Chaldal, Evaly, Pickaboo and Ajkerdeal - Forecasts to 2028
OVID

GlobeNewswire

a year ago

Bangladesh Ecommerce Market Report 2024, Featuring Daraz Bangladesh, Chaldal, Evaly, Pickaboo and Ajkerdeal - Forecasts to 2028

3 Major Product Releases at 3Shape Discover Event
OVID

PR Newswire

a year ago

3 Major Product Releases at 3Shape Discover Event

Calculating The Fair Value Of Mincon Group plc (LON:MCON)
OVID

Simply Wall St.

a year ago

Calculating The Fair Value Of Mincon Group plc (LON:MCON)

Flash News: OKX Launches 'Trade and Earn' Campaign Featuring 2,500,000 Ultiverse Tokens
OVID

GlobeNewswire

a year ago

Flash News: OKX Launches 'Trade and Earn' Campaign Featuring 2,500,000 Ultiverse Tokens

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
OVID

Zacks

2 years ago

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
OVID

GlobeNewswire

2 years ago

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
OVID

GlobeNewswire

2 years ago

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
OVID

Zacks

2 years ago

Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

OVID

MT Newswires

2 years ago

B. Riley Securities Initiates Ovid Therapeutics With Buy Rating, $9 Price Target

OVID

MT Newswires

2 years ago

HC Wainwright Starts Ovid Therapeutics With Buy Rating, $9 Price Target

Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
OVID

Zacks

2 years ago

Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
OVID

Simply Wall St.

2 years ago

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
OVID

GlobeNewswire

2 years ago

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Ovid Therapeutics Reaches US$197m Market Cap Benefiting Insider Stock Buying
OVID

Simply Wall St.

2 years ago

Ovid Therapeutics Reaches US$197m Market Cap Benefiting Insider Stock Buying

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
OVID

GlobeNewswire

2 years ago

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
OVID

GlobeNewswire

2 years ago

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
OVID

GlobeNewswire

2 years ago

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Share on Social Networks: